Ovarian cancer: 2012 Update Srini Prasad MD Univ Texas MD Anderson Cancer Center

Similar documents
Bases biológicas del cáncer de ovario en el siglo XXI

Patologia Molecular del Carcinoma de Ovario

3 cell types in the normal ovary

Current Concept in Ovarian Carcinoma: Pathology Perspectives

3 cell types in the normal ovary

Case 1. Pathology of gynecological cancer. What do we need to know (Case 1) Luca Mazzucchelli Istituto cantonale di patologia Locarno

Mousa. Najat kayed &Renad Al-Awamleh. Nizar Alkhlaifat

Ovarian carcinoma classification. Robert A. Soslow, MD

Dall istologia alla caratterizzazione biomolecolare

Invited Re vie W. Molecular genetics of ovarian carcinomas. Histology and Histo pathology

Institute of Pathology First Faculty of Medicine Charles University. Ovary

of 20 to 80 and subsequently declines [2].

Gynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:

Gynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health

Epithelial Ovarian Cancer 8/2/2013. Tu-be or Not Tu-be: Is the Fallopian Tube the Source of Ovarian Cancer?

Case presentation 04/13/2017. Genomic/morphological classification of endometrial carcinoma

ACCME/Disclosures. Risk of Gyne Ca in HBOC. Molecular basis of HBOC. Hereditary Ovarian and Breast Cancer Syndrome

Section 1. Biology of gynaecological cancers: our current understanding

Icd 10 ovarian stroma

The Diagnostic Challenges of Low Grade and High Grade Tubo-Ovarian Serous Carcinomas. W Glenn McCluggage Belfast, Northern Ireland

Pathology of Ovarian Tumours. Dr. Jyothi Ranganathan MD ( Path) AFMC Pune PDCC (Cytopathology) PGI Chandigarh

Low-grade serous neoplasia. Robert A. Soslow, MD

Ovarian Clear Cell Carcinoma

Cancer arising from Endometriosis and Its Clinical implications

International Society of Gynecological Pathologists Symposium 2007

Ovarian Cancer Causes, Risk Factors, and Prevention

The Origin of Pelvic Low-Grade Serous Proliferative Lesions

Primary Care Approach to Genetic Cancer Syndromes

How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens

Mucinous Tumors of the Ovary Beirut, Lebanon. Anaís Malpica, M.D. Professor Department of Pathology

Biology Response Controversies and Advances

Explaining Personalized Medicine in Cancer and Some Tips for a Healthier Life. Petra Ketterl, MD Integrative Medicine and Cancer Care

Background. Background. Background. Background 2/2/2015. Endometriosis-Associated Ovarian Cancer: Malignant Transformation of Endometriosis

Shina Oranratanaphan, Tarinee Manchana*, Nakarin Sirisabya

EDUCATIONAL COMMENTARY CA 125. Learning Outcomes

Presenter: Yeh-Han Wang M.D.

Development of Carcinoma Pathways

Endometrial cancer. Szabolcs Máté MD. I. St. Department of Obstetrics and Gyneacology.

Histopathological Study of Spectrum of Lesions Seen in Surgically Resected Specimens of Fallopian Tube

Serrated Polyps and a Classification of Colorectal Cancer

What s (new) and Important in Reporting of Uterine Cancers Katherine Vroobel The Royal Marsden

GENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By. Magnitude of the Problem. Magnitude of the Problem. Cardinal Features of Lynch Syndrome

Triage of Ovarian Masses. Andreas Obermair Brisbane

Characterizing Adnexal Masses: Pearls and Pitfalls 20 th Annual Summer Practicum SCBT-MR Jackson Hole August 11, 2010

AllinaHealthSystems 1

Beyond the APC era Alternative pathways to CRC. Jeremy R Jass McGill University

Clonal evolution of human cancers

Loss of Mismatch Repair Protein Expression in Epithelial Ovarian Carcinoma: A Histomorphologic Guide to Targeted Screening

Joseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital

Lavage of the uterine cavity as potential tool for diagnosis of epithelial ovarian cancer and its precursors

Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar

See the latest estimates for new cases of ovarian cancer and deaths in the US and what research is currently being done.

Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms

So how much of breast and ovarian cancer is hereditary? A). 5 to 10 percent. B). 20 to 30 percent. C). 50 percent. Or D). 65 to 70 percent.

Biology of Ovarian Cancer

Female Genital Tract Lab. Dr. Nisreen Abu Shahin Assistant Professor of Pathology University of Jordan

RESEARCH COMMUNICATION

GENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER. Dr Abhijit Dixit. Family Health Clinical Genetics

Case Report Ovarian Seromucinous Borderline Tumor and Clear Cell Carcinoma: An Unusual Combination

Test Bank for Robbins and Cotran Pathologic Basis of Disease 9th Edition by Kumar

Disclosure. Objectives

Survival Analysis and Prognosis for Patients with Serous and Mucinous Borderline Ovarian Tumors: 14-Year Experience from a Tertiary Center in Iran

OVARIES. MLS Basic histological diagnosis MLS HIST 422 Semester 8- batch 7 L13 Dr: Ali Eltayb.

B Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696

Assessment of Universal Mismatch repair (MMR) or Microsatellite Instability (MSI) testing in colorectal cancers.

SCREENING FOR OVARIAN CANCER DR MACİT ARVAS

Borderline tumors. Borderline tumors. Serous borderline tumor are NOT benign. Low grade serous carcinoma: pathogenesis. Serous carcinoma: pathogenesis

Hereditary Non Polyposis Colorectal Cancer(HNPCC) From clinic to genetics

H&E, IHC anti- Cytokeratin

The Role of Genetics in Ovarian Cancer Screening. Dawn DeLozier, Ph.D. Medical Geneticist, SAMC Associate Professor UCSF-Fresno

Sarah Burton. Lead Gynae Oncology Nurse Specialist Cancer Care Cymru

Is CA-125 the Leading Biomarker in Determining Early-Onset Ovarian Cancer Diagnosis in 2016?

Mody. AIS vs. Invasive Adenocarcinoma of the Cervix

Locoregional delivery of unmethylated CpG-oligodeoxynucleotides to cancer therapy: preclinical studies

Endosalpingiosis. Case report

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

11/29/2017. Genetics and Cancer ERICA L SILVER, MS, LCGC GENETIC COUNSELOR. Genetics 101. Transcription vs Translation

Is It Time To Implement Ovarian Cancer Screening?

Measure Description. Denominator Statement

Molecular markers in colorectal cancer. Wolfram Jochum

Risk of Colorectal Cancer (CRC) Hereditary Syndromes in GI Cancer GENETIC MALPRACTICE

6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017

Springer Healthcare. Understanding and Diagnosing Ovarian Cancer. Concise Reference: Krishnansu S Tewari, Bradley J Monk

Familial and Hereditary Colon Cancer

Primary Mucinous Ovarian Cancer (PMOC) Michael Frumovitz

Endometrial adenocarcinoma icd 10 code

Joshua Cohen MD Gynecologic Oncology Fellow UCLA/Cedars-Sinai Medical Center

General Session 7: Controversies in Screening and Surveillance in Colorectal Cancer

Universal BRCA1 and BRCA2 Genetic Testing for Ovarian Cancer Patients

Célia DeLozier-Blanchet

Molecular Subtyping of Endometrial Cancer: A ProMisE ing Change

The molecular genetics of endometrial cancer

Interpretation of p53 Immunostains. P53 Mutations are Ubiquitous in High Grade Serous Carcinoma. Diffuse strong positive nuclear staining

Colorectal adenocarcinoma leading cancer in developed countries In US, annual deaths due to colorectal adenocarcinoma 57,000.

5/26/2016. Pelvic Serous Carcinoma: 2014 W.H.O. Update. Outline of Talk. Changes to 2014 WHO system for pelvic serous tumors

Published Ahead of Print on September 28, 2012 as /theoncologist

Multistep nature of cancer development. Cancer genes

Pathology of the female genital tract

Pancreatic intraepithelial

Ovarian Cancer What you need to know

Transcription:

Ovarian cancer: 2012 Update Srini Prasad MD Univ Texas MD Anderson Cancer Center

Ovarian cancer is not a single disease

Ovarian Epithelial Tumors: Histological Spectrum* Type Frequency Histology High-Grade Serous Carcinoma 60-65% Low-Grade Serous Carcinoma 5% Endometrioid Carcinoma 10-15% Clear cell Carcinoma 10% *2002 World Health Organization Classification of Ovarian Tumors

Ovarian Epithelial Tumors: Histological Spectrum* Type Frequency Histology Transitional Carcinoma 5% Mucinous Carcinoma <5% *2002 World Health Organization Classification of Ovarian Tumors

10% ovarian cancers are hereditary

Ovarian Carcinoma: Hereditary syndromes Hereditary forms: Distinct clinicopathological features Mutations of tumor-suppressor genes BRCA 1 & 2 (90%) Ovarian cancer syndrome Breast & Ovarian cancer syndrome Mutations of DNA MisMatch Repair (MMR) genes hmlh1 & hmsh2 (10%) Hereditary non-polyposis colorectal cancer HNPCC (Lynch-II) Finch et al. Gynecol Oncol 2006;100:58-64

Ovarian Carcinoma: Risk Stratification Sporadic HNPCC BRCA1 BRCA2 Syndrome mutation Mutation Lifetime risk for Ovarian Ca 1-2% 12% 40-50% 20-30% Finch et al. Gynecol Oncol 2006;100:58-64

BRCA-1 syndrome: Ovarian cancer

BRCA 2 syndrome: Ovarian cancer

Adnexal carcinomas?

Adnexal carcinomas? The era of indifference to the fallopian tube has passed Pauerstein & Woodruff. Txt on Fallopian Tube.1969

High-grade Ovarian Serous Carcinoma

Ovarian cancers develop from microscopic & macroscopic precursor lesions

Serous Ovarian Carcinoma: Step-wise progression Cystadenoma Serous borderline tumor Low-grade serous carcinoma

Ovarian Carcinoma: Carcinogenesis Histology High-grade Serous Carcinoma Precursor lesions Serous tubal intraepithelial carcinoma Low-grade Serous Carcinoma Serous cystadenoma, adenofibroma Serous Borderline Tumor Mucinous Carcinoma Mucinous cystadenoma Mucinous Borderline Tumor

Ovarian Carcinoma: Carcinogenesis Histology Endometrioid Carcinoma Clear cell Carcinoma Precursor lesions Endometriosis Endometrioid borderline tumor or adenofibroma Endometriosis Clear cell adenofibroma, Borderline Tumor Malignant Brenner neoplasm Brenner neoplasm Borderline Brenner Tumor

Endometriosis Associated Ovarian Carcinoma 40% of endometrioid carcinomas are associated with endometriosis 50% of clear cell carcinomas are associated with endometriosis

Endometriosis Associated Ovarian Carcinoma 1-2% of endometriosis show malignant change Sequential genetic changes cause malignant transformation EAOC is typically low stage/low grade, predominantly clear-cell (most common subtype) or endometrioid type, & portend a better prognosis

Endometriosis Associated Ovarian Carcinoma Endometrium β-catenin,il-6 ER,PR Endometriosis PTEN,hMLH1 LOH 9p,11q,22q Atypical Endometriosis PTEN, TP53 β-catenin, LOH 6q,5q Endometrioid / Clear Cell Cancer *Sequential Cytogenetic March of Endometriosis to Endometriosis-Associated Ovarian Carcinoma

Metastatic mucinous cancer from the appendix

Metastatic mucinous cancer from sigmoid colon primary

Ovarian Epithelial Carcinoma: Histogenesis?Fallopian tube/ Ovary? Epithelial inclusion cysts? Secondary Mullerian system Endometriosis TP53 & BRCA mutations BRAF/KRAS mutations PTEN/β-catenin mutations PTEN/PI3KCA mutations Borderline Tumor High Grade Serous Ca Low Grade Serous Ca Endometrioid Carcinoma Clear cell Carcinoma Katre R. Am J Roentgenol; Lalwani N. Radiographics

Each ovarian cancer subtype shows distinctive genetics & biology

Molecular Genetics in Clinical Practice The Devil is in the DNA *Chanock, Thomas. Nat Genet 2007;39(3):283-4

Ovarian Carcinoma: Carcinogenesis Histology Precursor lesions Mutations High-grade Serous Carcinoma Low-grade Serous Carcinoma Mucinous Carcinoma Serous tubal intraepithelial carcinoma Serous cystadenoma, adenofibroma Serous Borderline Tumor Mucinous cystadenoma Mucinous Borderline Tumor TP-53 (60-80%) HER2/neu gene (10-20%) AKT2 gene (12-18%) B-raf, K-ras (>2/3 tumors) K-ras (>60%)

Ovarian Carcinoma: Carcinogenesis Histology Precursor lesions Mutations Endometrioid Carcinoma Clear cell Carcinoma Malignant Brenner neoplasm Endometriosis Endometrioid borderline tumor or adenofibroma Endometriosis Clear cell adenofibroma, Borderline Tumor Brenner neoplasm Borderline Brenner Tumor CTNNB-1 (>1/3 cancers) PTEN/PI3KCA (40%) MSI ( Up to 20%) PI3KCA (33%) HNF-1β/IL6-STAT/HIF- 1α HER2/neu gene Not well characterized

Ovarian carcinoma: Chemotherapy Cancers are like cockroaches; both are difficult to kill.

Ovarian cancer: Conclusions Ovarian cancers are histo-pathologically heterogeneous Most ovarian cancers likely arise from outside the ovary Biological diversity: type 1 are indolent, usually confined to the ovary; type 2 are widely metastatic High grade serous is platinum sensitive; low grade serous, mucinous & clear cell cancers are chemo-resistant?changes in screening, prophylaxis, prognosis &treatment paradigms